Literature DB >> 24096540

RhoA and RhoC differentially modulate estrogen receptor α recruitment, transcriptional activities, and expression in breast cancer cells (MCF-7).

Emilie Malissein1, Elise Meunier, Isabelle Lajoie-Mazenc, Claire Médale-Giamarchi, Florence Dalenc, Sophie F Doisneau-Sixou.   

Abstract

PURPOSE: RhoA and RhoC are closely related, small GTPases that are clearly involved in breast cancer tumorigenesis. Nonetheless, their specific roles in the control of estrogen receptor alpha (ERα) activities have not been elucidated.
METHODS: We used siRNA sequences to specifically down-regulate RhoA and RhoC expression in ERα-positive breast adenocarcinoma MCF-7 cells. We then analyzed the consequences of down-regulation on ERα expression, ERα recruitment to the promoters of four target genes, and the mRNA levels of those genes.
RESULTS: We demonstrated that RhoA and RhoC clearly and similarly modulated ERα recruitment to the vitellogenin estrogen responsive element (ERE) present in a luciferase reporter gene and to the promoters of progesterone receptor (PR), cathepsin D, and pS2 genes. Besides, RhoA up-regulated the ERE-luciferase reporter gene activity and PR mRNA expression and tended to down-regulate cathepsin D and pS2 mRNA expression. Conversely, RhoC inhibition had no significant effect at the mRNA level. Furthermore, RhoA inhibition, and to a lesser extent RhoC inhibition, increased ERα expression. No alteration in ERα mRNA levels was observed, suggesting potential post-translational control.
CONCLUSIONS: Taken together, our results strongly suggest that RhoA and RhoC play different, but clear, roles in ERα signaling. These GTPases are definitely involved, along with RhoB, in ERα recruitment and, to some extent, ERα cofactor balance. We hypothesize a differential role of RhoA in breast cancer tumors that depend on hormone status.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24096540     DOI: 10.1007/s00432-013-1533-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  55 in total

1.  Rho proteins crosstalk via RhoGDIalpha: At random or hierarchically ordered?

Authors:  Audrey Stultiens; T T Giang Ho; Betty V Nusgens; Alain C Colige; Christophe F Deroanne
Journal:  Commun Integr Biol       Date:  2012-01-01

2.  Genome-wide analysis of estrogen receptor binding sites.

Authors:  Jason S Carroll; Clifford A Meyer; Jun Song; Wei Li; Timothy R Geistlinger; Jérôme Eeckhoute; Alexander S Brodsky; Erika Krasnickas Keeton; Kirsten C Fertuck; Giles F Hall; Qianben Wang; Stefan Bekiranov; Victor Sementchenko; Edward A Fox; Pamela A Silver; Thomas R Gingeras; X Shirley Liu; Myles Brown
Journal:  Nat Genet       Date:  2006-10-01       Impact factor: 38.330

Review 3.  RhoGDI signaling provides targets for cancer therapy.

Authors:  Michael A Harding; Dan Theodorescu
Journal:  Eur J Cancer       Date:  2010-03-27       Impact factor: 9.162

4.  Rho GTPases as modulators of the estrogen receptor transcriptional response.

Authors:  L F Su; R Knoblauch; M J Garabedian
Journal:  J Biol Chem       Date:  2000-11-01       Impact factor: 5.157

Review 5.  Role of Rho GTPases in breast cancer.

Authors:  Yong Tang; Lola Olufemi; Man-Tzu Wang; Daotai Nie
Journal:  Front Biosci       Date:  2008-01-01

6.  RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease.

Authors:  Antonia Bellizzi; Anita Mangia; Annalisa Chiriatti; Stella Petroni; Michele Quaranta; Francesco Schittulli; Andrea Malfettone; Rosa Angela Cardone; Angelo Paradiso; Stephan Joel Reshkin
Journal:  Int J Mol Med       Date:  2008-07       Impact factor: 4.101

7.  Rho GDP dissociation inhibitor alpha expression correlates with the outcome of CMF treatment in invasive ductal breast cancer.

Authors:  Henrike Ronneburg; Paul N Span; Eva Kantelhardt; Angela Dittmer; Dario Schunke; Hans-Jürgen Holzhausen; Fred C G J Sweep; Jürgen Dittmer
Journal:  Int J Oncol       Date:  2010-02       Impact factor: 5.650

8.  MAP1A light chain-2 interacts with GTP-RhoB to control epidermal growth factor (EGF)-dependent EGF receptor signaling.

Authors:  Isabelle Lajoie-Mazenc; Daniel Tovar; Marie Penary; Barbara Lortal; Sophie Allart; Cyril Favard; Meryem Brihoum; Anne Pradines; Gilles Favre
Journal:  J Biol Chem       Date:  2007-12-03       Impact factor: 5.157

9.  Prenylation inhibitors stimulate both estrogen receptor alpha transcriptional activity through AF-1 and AF-2 and estrogen receptor beta transcriptional activity.

Authors:  Philippe Cestac; Guillaume Sarrabayrouse; Claire Médale-Giamarchi; Philippe Rochaix; Patrick Balaguer; Gilles Favre; Jean-Charles Faye; Sophie Doisneau-Sixou
Journal:  Breast Cancer Res       Date:  2004-11-08       Impact factor: 6.466

10.  RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor.

Authors:  Claire Médale-Giamarchi; Isabelle Lajoie-Mazenc; Emilie Malissein; Elise Meunier; Bettina Couderc; Yann Bergé; Thomas Filleron; Laura Keller; Claudine Marty; Magali Lacroix-Triki; Florence Dalenc; Sophie F Doisneau-Sixou; Gilles Favre
Journal:  Breast Cancer Res       Date:  2013-01-22       Impact factor: 6.466

View more
  4 in total

Review 1.  Minireview: Mouse Models of Rho GTPase Function in Mammary Gland Development, Tumorigenesis, and Metastasis.

Authors:  Yan Zuo; Wonkyung Oh; Arzu Ulu; Jeffrey A Frost
Journal:  Mol Endocrinol       Date:  2015-12-17

2.  A high expression ratio of RhoA/RhoB is associated with the migratory and invasive properties of basal-like Breast Tumors.

Authors:  Maud Privat; Amélie Cavard; Yanis Zekri; Flora Ponelle-Chachuat; Ioana Molnar; Nicolas Sonnier; Yves-Jean Bignon
Journal:  Int J Med Sci       Date:  2020-10-01       Impact factor: 3.738

3.  A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells.

Authors:  Yosi Gilad; Yossi Eliaz; Yang Yu; Adam M Dean; San Jung Han; Li Qin; Bert W O'Malley; David M Lonard
Journal:  Commun Biol       Date:  2021-03-25

4.  Obesity alters the ovarian proteomic response to zearalenone exposure†.

Authors:  M Estefanía González-Alvarez; Bailey C McGuire; Aileen F Keating
Journal:  Biol Reprod       Date:  2021-07-02       Impact factor: 4.285

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.